RxDoctor Payments Data

Hugh Durham, MD

Infectious Disease · Atlanta, GANPI 1669542023

Payments from drug & device makers

$4,397in general payments, 2019–2025

Across 239 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$913
  • Merck$414
  • AbbVie$278
  • Johnson & Johnson$267
  • Theratechnologies Inc.$226
  • plus $911 from 15 others

What the payments were for

  • Food & beverage$4,20896%
  • Education$1894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,397 in reported general payments places this provider in the 65th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$71,478
Medicare patients
96
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala181$839,088
TriumeqAbacavir/Dolutegravir/Lamivudi78$311,672
TivicayDolutegravir Sodium103$311,484
GenvoyaElviteg/Cob/Emtri/Tenof Alafen32$126,819
PrezcobixDarunavir/Cobicistat49$123,791
Gamunex-CImmune Globul G/Gly/Iga Avg 4623$101,020
DescovyEmtricitabine/Tenofov Alafenam44$93,621
DovatoDolutegravir Sodium/Lamivudine32$91,721
OdefseyEmtricitab/Rilpiviri/Tenof Ala23$83,132
DelstrigoDoravirine/Lamivu/Tenofov Diso26$74,420
Darunavir31$26,124
IsentressRaltegravir Potassium13$25,539
AbacavirAbacavir Sulfate21$9,867
Testosterone14$9,510
Ritonavir22$9,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,387$1,059,528257 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato$913$714,877213 claims
Johnson & JohnsonPrezcobix$267$123,79149 claims
Grifols USA, LLCGamunex-C$38$101,02023 claims
MerckDelstrigo, Isentress$414$99,95939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →